July 26, 2025
On July 23, 2025, AstraZeneca released final overall survival results from the Phase III FLAURA2 trial in treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Patients receiving osimertinib (Tagrisso) combined with platinum-based chemotherapy achieved a statistically significant OS advantage over Tagrisso monotherapy, with a hazard ratio of0.75. Median OS was not reached in the combination arm, compared to 36.7 months with monotherapy. Safety data revealed Grade ≥3 adverse events in 16% of patients during maintenance chemotherapy, and a 3.3% incidence of interstitial lung disease/pneumonitis, including one death. These findings mark a landmark shift, defining a robust combinatorial approach in first-line EGFRm NSCLC that competes directly with the RYB+LAZ (amivantamab + lazertinib) regimen.
Citation: https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-with-the-addition-of-chemotherapy-approved-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer.html?utm_source=chatgpt.com
Implication:
The OS advantage reinforces Tagrisso + chemo as a credible challenge toRYB+LAZ, potentially affecting guidelines and payer considerations. As a well-established brand, it may limit selective uptake of novel combinations unless RYB+LAZ demonstrates superior real-world tolerability or convenience.